The Biotechnology Innovation Organization (BIO) unveiled “BioAdvance: Securing America’s Biotech Century,” a seven-point national action plan aimed at maintaining U.S. leadership in biotechnology amid intensifying competition from China. The proposal calls for coordinated government action, faster clinical development timelines, and expanded domestic research and manufacturing capacity. BIO’s plan includes setting up a White House Office of Biotechnology, accelerating the path to first-in-human studies, modernizing and streamlining drug development, and improving patient access to clinical trials. BIO also urges sustained support for biomedical research, expansion of U.S. biomanufacturing capacity, strengthened intellectual property protections, and expanded access to capital. The plan frames China’s state-backed ramp in biotech as a strategic driver, citing rapid growth in China’s clinical trial activity and industry scale. BIO President and CEO John F. Crowley said American biotech leadership is “not guaranteed” and requires investment and urgency to preserve competitiveness. For biotech executives, the proposal signals a potential policy agenda that could affect trial infrastructure, regulatory coordination, incentives for domestic manufacturing, and the flow of R&D funding and capital—particularly as U.S. lawmakers weigh how to respond to China-originated deal activity and expanding trial volume.